

## Is It Time to Reconsider Your Treatment Strategy in Your Patients with T2D?

Register Now

**Webinar Program Overview:** Explore efficacy and safety data for 2 GLP-1 RA options for adults with T2D. A data review from pivotal glycemic control trials as well as cardiovascular outcomes data will be presented.

### Available Programs:

- Tuesday, October 20, 2020 @ 7:00 PM Eastern
- Wednesday, October 21, 2020 @ 2:00 PM Eastern

**Program Duration:** 45-minute scientific presentation & 15 minutes of Q&A



### Faculty Presenter:

**Jonathan G. Marquess, PharmD, CDE, FAPhA**

President/CEO

The Marquess Group of Independent Pharmacies

The Institute for Wellness & Education, a Disease Management Company

Woodstock, Georgia

Register Now

**There is no registration fee for your participation.**

**This program is sponsored by Novo Nordisk.**

This is a promotional education presentation; it will not be certified for continuing medical education credit.

Presentations contain product-related education.

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this educational program is limited to healthcare professionals. Accordingly, attendance by guests or spouses is not appropriate and cannot be accommodated.

### Unsubscribe Notice

If you no longer want to receive communications from Novo Nordisk, click here to [unsubscribe](#). You may call us at 1.877.744.2579 or send us a letter that includes your full contact information (eg name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our [Privacy Statement](#).

Novo Nordisk is a registered trademark of Novo Nordisk A/S.